共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
3.
Background:Dyslipidemia is a main risk factor of cardiovascular disease in the diabetic patients. Niacin was found acutely to decrease the plasma concentration of free fatty acids by inhibiting their mobilization from adipose tissue. This present study is a double blinded, randomized, and prospective trial to determine the effect of niacin during dyslipidemia in type 2 diabetic patients.Methods:This randomized controlled, double-blinded, single center trial is carried out according to the principles of Declaration of Helsinki. This present study was approved in institutional review committee of the Second Affiliated Hospital of Dalian Medical University. All the patients received the informed consent. Diabetic patients were randomized (1:1) to receive 3-month treatment with extended-release niacin or matching placebo. The major outcome of our present study was the change in the level of HbA1c from the baseline to week 12. Secondary outcome measures contained the levels of fasting blood glucose, the concentrations of serum transaminase, the other laboratory variables, and self-reported adverse events. The P < .05 was regarded as statistically significant.Results:We assumed that adding the niacin to the medication in patients with type 2 diabetes would reduce dyslipidemia and achieve target lipid levels.Trial registration:This study protocol was registered in Research Registry (researchregistry5925). 相似文献
4.
5.
6.
7.
8.
9.
Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin‐associated weight gain: 52‐week results from the Effect of Liraglutide on insulin‐associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized controlled trial 下载免费PDF全文
H. M. de Wit G. M. Vervoort H. J. Jansen B. E. de Galan C. J. Tack 《Journal of internal medicine》2016,279(3):283-292
10.
Marconi Abreu MD Anna Tumyan MD Ahmed Elhassan MD Katherine Peicher DO Olivia Papacostea MD Perihan Dimachkie MD Muhammad S. Siddiqui MD Laurentiu M. Pop MD Uma Gunasekaran MD Luigi F. Meneghini MD Beverley Adams-Huet MS Xilong Li PhD Ildiko Lingvay MD 《Diabetes, obesity & metabolism》2019,21(9):2133-2141
11.
Short‐term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial 下载免费PDF全文
J. Skov M. Pedersen J. J. Holst B. Madsen J. P. Goetze S. Rittig T. Jonassen J. Frøkiær A. Dejgaard J. S. Christiansen 《Diabetes, obesity & metabolism》2016,18(6):581-589
12.
Emilie H. Zobel MD Bernt J. von Scholten DMSc Bryan Goldman MS Frederik Persson DMSc Tine W. Hansen PhD Peter Rossing DMSc 《Diabetes, obesity & metabolism》2019,21(5):1261-1265
Liraglutide has pleiotropic effects favouring cardiovascular and renal risks. We investigated individual responses to liraglutide in six cardio-renal risk factors to examine whether responses in one risk factor are associated with changes in other risk factors (cross-dependency). We performed secondary analysis of the LIRA-RENAL trial (n = 279) in type 2 diabetes. HbA1c, body weight, systolic blood pressure (SBP), low density lipoprotein (LDL)-cholesterol, urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) were measured at baseline and after 26 weeks of liraglutide/placebo treatment: “Good responders” had a change within the best quartile. In the liraglutide-treated group, good HbA1c responders showed similar changes in other risk factors analysed to low responders (P ≥ 0.17). Good body weight responders had a larger reduction in HbA1c than low body weight responders (−1.6 ± 0.94 vs. –1.0 ± 0.82%; P = 0.003), but similar changes in the other risk factors (P ≥ 0.11). Good and low responders in SBP, UACR, LDL-cholesterol or eGFR showed similar changes in other risk factors (P ≥ 0.07). Treatment response to liraglutide is largely individual; aside from an association between body weight and HbA1c reduction, there are no obvious cross-dependencies in risk factor response. 相似文献
13.
14.
Francisco J. Pasquel MD Maria A. Urrutia MD Saumeth Cardona MD Karla W. Z. Coronado MD Bonnie Albury Mireya C. Perez-Guzman Rodolfo J. Galindo Ajay Chaudhuri MD Gianluca Iacobellis MD Juan Palacios MD Javier M. Farias MD Patricia Gomez MD Isabel Anzola MD Priyathama Vellanki MD Maya Fayfman MD Georgia M. Davis MD Alexandra L. Migdal MD Limin Peng PhD Guillermo E. Umpierrez MD 《Diabetes, obesity & metabolism》2021,23(6):1351-1360
15.
Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA‐SWITCH): a randomized,double‐blind,double‐dummy,active‐controlled 26‐week trial 下载免费PDF全文
T. S. Bailey MD R. Takács MD F. J. Tinahones MD P. V. Rao MD G. M. Tsoukas MD A. B. Thomsen MD M. S. Kaltoft MD M. Maislos MD 《Diabetes, obesity & metabolism》2016,18(12):1191-1198
16.
Ehtasham Ahmad MRCP Helen L. Waller PhD Jack A. Sargeant PhD M'Balu A. Webb PhD Zin Zin Htike PhD Gerry P. McCann MD Gaurav Gulsin PhD Kamlesh Khunti FMedSci Tom Yates PhD Joseph Henson PhD Melanie J. Davies MD David R. Webb PhD 《Diabetes, obesity & metabolism》2021,23(6):1409-1414
The mechanisms behind the beneficial cardiovascular effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) compared with dipeptidyl peptidase-4 inhibitors (DPP4is) remain largely unknown, despite both targeting the incretin pathway to improve glycaemic control. In these prespecified secondary analyses of the LYDIA trial, we examined the impact of the GLP-1RA liraglutide (1.8 mg once-daily) and the DPP4i sitagliptin (100 mg once-daily) on circulating cardiovascular biomarkers associated with atherosclerotic risk, including circulating progenitor cells (CPCs). LYDIA was a 26-week, randomized, active-comparator trial in 61 adults with type 2 diabetes and obesity (mean ± SD: age 43.8 ± 6.5 years, body mass index 35.3 ± 6.4 kg/m2, HbA1c 7.5% ± 0.83% [58.5 ± 9.1 mmol/mol]). Vascular endothelial growth factor (VEGF) and stromal cell-derived factor-1-alpha (SDF-1ɑ), both of which are implicated in endothelial function, were higher at 26 weeks with liraglutide therapy compared with sitagliptin (mean between-group difference [95% CI]: 77.03 [18.29, 135.77] pg/mL, p = .010; and 996.25 [818.85, 1173.64] pg/mL, p < .001, respectively). There were no between-group differences in CPCs, nitric oxide, C-reactive protein, interleukin-6, tumour necrosis factor alpha and advanced glycation end-products. These analyses suggest a favourable impact of liraglutide on VEGF and SDF-1ɑ levels compared with sitagliptin. These factors may therefore be implicated in the differential cardiovascular effects observed between these agents in large cardiovascular outcome trials. However, these are secondary analyses from a previous trial and thus hypothesis-generating. Purposive trials are required to examine these findings further. 相似文献
17.
L. J. Gray M. A. Saeed D. Smith W. Hanif K. Khunti 《Diabetes, obesity & metabolism》2014,16(6):527-536
18.
Background:No studies were located which used a web-based educational intervention to improve the knowledge about newly diagnosed type 2 diabetes mellitus (T2DM). Therefore, the primary objective of the present study was to evaluate the efficacy of web-based educational intervention on psychological outcomes and glycemic control in newly diagnosed T2DM in rural China.Methods:This work is a part of a comprehensive research project to assess and provide educational intervention that potentially improve psychological status and blood glucose among patients with T2DM. Eligibility criteria for the study includes newly diagnosed with T2DM, adult patients (age ≥30 years) regardless of gender; speak and understand Chinese languages; having no significant comorbidity; being not involved in any trial/study related to diabetes during last 3 months and able to attend regular visits. Eligible participants were divided into 2 groups according to completely randomized design: education group and control group. The outcomes included fasting blood glucose level, EQ-5D-3L questionnaire, Self-rating Anxiety Scale, and Self-rating Depression Scale.Results:This protocol will provide a reliable theoretical basis for the following research.Conclusion:The sample came from a single health centre. Therefore, the results can not be generalized for the entire population.Trial registration:This study protocol was registered in Research Registry (researchregistry6511). 相似文献
19.
20.
Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial 下载免费PDF全文
Kohei Kaku MD Yuichiro Yamada MD Hirotaka Watada MD Atsuko Abiko MD Tomoyuki Nishida MSc Jeppe Zacho MD Arihiro Kiyosue MD 《Diabetes, obesity & metabolism》2018,20(5):1202-1212